A high placebo relapse rate was also observed for patients with a baseline MADRS below median , while low escitalopram relapse rates were characteristic of patients who had achieved remission by Week 6 or 8 ( HR = 8.9 ) , had a current depressive episode length below median , baseline MADRS below median ( HR = 11.8 ) , or received 10mg for 12 weeks ( HR = 6.3 ) .